A randomized, parallel group, double-blind, placebo controlled, 14 days multiple-dose treatment to assess the pulmonary and cardiac pharmacodynamics of FTY720 [fingolimod] (0.5 and 1.25 mg) in healthy volunteers

Trial Profile

A randomized, parallel group, double-blind, placebo controlled, 14 days multiple-dose treatment to assess the pulmonary and cardiac pharmacodynamics of FTY720 [fingolimod] (0.5 and 1.25 mg) in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2011

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 11 Jun 2010 According to a Novartis media release, an FDA advisory committee has unanimously recommended the approval of Novartis investigational treatment FTY720 to treat relapsing remitting Multiple Sclerosis.
    • 03 Jun 2010 Patient numbers amended from 38 to 39 as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top